ATH ASX News

3 December 2024

Alterity Announces Completion of Phase 2 Clinical Trial

Alterity Therapeutics finishes last patient visit for ATH434-201 trial; topline data expected early 2025.

Alterity Therapeutics Clinical Trial Multiple System Atrophy Biotechnology Neurodegenerative Diseases

Posted on: 03/12/2024

Read More

17 July 2024

Positive Interim Data from ATH434-202 Phase 2 Clinical Trial

Alterity Therapeutics announces positive interim data from ATH434-202 Phase 2 trial in MSA patients.

Alterity Therapeutics ATH434 Multiple System Atrophy Clinical Trial Biotechnology

Posted on: 17/07/2024

Read More